An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REGARD
- Sponsors Bayer
- 01 Dec 2017 Planned End Date changed from 30 Oct 2017 to 15 Jan 2018.
- 20 Oct 2017 Planned End Date changed from 29 Sep 2017 to 30 Oct 2017.
- 06 Sep 2017 Planned End Date changed from 31 Aug 2017 to 29 Sep 2017.